bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.bioAffinity Technologies reported Q2 2026 revenue of $1.51M, a 19% YoY increase, while narrowing its net loss to $3.37M and reporting diluted EPS of $(0.64). Key highlights include a 156% rise in CyPath Lung revenue, a 122% expansion in ordering physicians, and the opening of 11 trial sites for longitudinal studies. The company also advanced diagnostics and siRNA therapeutics with positive preclinical results.
bioAffinity Technologies, Inc. reported second-quarter 2026 results with revenue of $1.51M, a 19% increase versus the year‑ago quarter, while the company narrowed its net loss to $3.37M and reported diluted loss per share of $(0.64).
Financial Highlights
- Revenue: $1.51M for Q2 2026, up from $1.27M in the year‑ago quarter (19% YoY).
- Net income: Net loss of $3.37M for Q2 2026, improved from a net loss of $4.06M in the year‑ago quarter.
- Diluted EPS: $(0.64) per share for Q2 2026, versus $(5.07) per share in the year‑ago quarter.
Business Highlights
- CyPath® Lung momentum: Year-to-date CyPath Lung revenue rose about 156%, and unit sales increased 216% in Q2, reflecting accelerating physician adoption.
- Channel shift: The acquisition of Village Oaks and transition to in-house PPLS lab operations enabled direct commercialization of testing.
- Market traction: Ordering physicians expanded 122% in Q2; more than 1,200 tests had been reported by July, alongside a published clinical white paper.
- Clinical and pipeline progress: Opened 11 trial sites (including nine VA/military locations) for a longitudinal trial started March 2026 with patient enrollment underway; advancing diagnostics for lung inflammation and topical siRNA therapeutics with positive preclinical and early results.
Original SEC Filing: bioAffinity Technologies, Inc. [ BIAF ] - 10-Q - Aug. 07, 2026